OBSV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Mar 2023 @ 16:00):

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy...

Stats
Today's Volume	8.23M
Average Volume	7.95M
Market Cap	11.00M
EPS	$0 ( 2024-03-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.138
ATR14	$0.0240 (28.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-06	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-28	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-23	Brown William Michael	Buy	250 000	Employee Stock Option (right to buy)
2023-01-01	Loumaye Ernest	Sell	0	Common Stock
2023-01-01	Mathers Edward T	Sell	32 000	Stock Option (right to buy)

INSIDER POWER
77.02
Last 14 transactions
Buy: 8 250 000 \| Sell: 1 374 140

Volume Correlation

Long: 0.13 (neutral)

Short: 0.22 (neutral)

Signal:(39.484) Neutral

Obseva SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Obseva SA Correlation - Currency/Commodity

-0.64
( weak negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.22
( neutral )

Obseva SA Financials

Annual	2022
Revenue:	$19.64M
Gross Profit:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2022
Revenue:	$19.64M
Gross Profit:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.337

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.670

Financial Reports:

No articles found.

Obseva SA

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.